التفاصيل البيبلوغرافية
| العنوان: |
Empagliflozin and colchicine in patients with reduced left ventricular ejection fraction following ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: a study protocol for a randomized, double-blinded, three-arm parallel-group, controlled trial |
| المؤلفون: |
Sajad Khiali, Mohammadreza Taban-Sadeghi, Parvin Sarbakhsh, Naser Khezerlouy-Aghdam, Hossein Namdar, Rezvanieh Salehi, Afra Rezagholizadeh, Taher Entezari-Maleki |
| المصدر: |
Trials, Vol 24, Iss 1, Pp 1-12 (2023) |
| بيانات النشر: |
BMC, 2023. |
| سنة النشر: |
2023 |
| المجموعة: |
LCC:Medicine (General) |
| مصطلحات موضوعية: |
Empagliflozin, Colchicine, Myocardial infarction, Heart failure, LVSD, Clinical trial, Medicine (General), R5-920 |
| الوصف: |
Abstract Background Patients with acute myocardial infarction are at greater risk for chronic heart failure and mortality. Currently, there is limited evidence supporting the beneficial effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular outcomes in non-diabetic patients with reduced left ventricular ejection fraction following acute myocardial infarction. Furthermore, the clinical effects of the combination of standard-dose sodium-glucose cotransporter-2 inhibitors with colchicine and high-dose sodium-glucose cotransporter-2 inhibitors in this setting have not been evaluated yet. Methods A prospective, double-blinded, parallel-group, placebo control randomized trial will be carried out at Shahid Madani Heart Center, the largest teaching referral hospital for cardiovascular diseases, affiliated with Tabriz University of Medical Sciences. A total of 105 patients with reduced left ventricular ejection fraction (≤ 40%) following the first episode of ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention with stent insertion will be randomized 1:1:1 to receive empagliflozin 10 mg daily, a combination of empagliflozin 10 mg daily and colchicine 0.5 mg twice daily, or empagliflozin 25 mg daily for 12 weeks. The primary outcomes are changes in the New York Heart Association functional classification and high-sensitivity C-reactive protein from the randomization through week 4 and week 12. Discussion The present study will be the first trial to evaluate the efficacy and safety of early treatment with the combination of standard-dose empagliflozin and colchicine as well as high-dose empagliflozin in non-diabetic patients with reduced left ventricular ejection fraction following ST-elevation myocardial infarction. The results of this research will represent a significant step forward in the treatment of patients with acute myocardial infarction. Trial registration Clinical trial ID: IRCT20111206008307N39. Registration date: 27 October 2022. Graphical Abstract |
| نوع الوثيقة: |
article |
| وصف الملف: |
electronic resource |
| اللغة: |
English |
| تدمد: |
1745-6215 |
| Relation: |
https://doaj.org/toc/1745-6215 |
| DOI: |
10.1186/s13063-023-07682-6 |
| URL الوصول: |
https://doaj.org/article/e585197e8024439ab6636c962f435614 |
| رقم الانضمام: |
edsdoj.585197e8024439ab6636c962f435614 |
| قاعدة البيانات: |
Directory of Open Access Journals |
Full Text Finder